KUALA LUMPUR (Dec 4): MyEG Services Bhd (MyEG) has secured a three-year extension for the e-government services it provides.
In a bourse filing today, the group said the Ministry of Transport (MoT) had granted the extension from May 23, 2020 to May 22, 2023.
It said the extension is in the best interest of the company, and expected to contribute positively to earnings and net assets per share of the company for the financial year ending Dec 31, 2020 (FY20) and thereafter.
“An agreement to formalise the extension will be signed and announced by the company in due course,” it said.
On May 23, 2000, MyEG entered into a concession agreement with the government for the electronic delivery of driver and vehicle registration, licensing and summons services, and utility bill payments (e-services) for a minimum tenure of 15 years.
On May 21, 2020, the group received an official notification from the government to continue with the provision of the e-government services until June 30, 2020.
At the noon break today, MyEG was 18 sen or 10.84% higher at RM1.84, valuing the group at RM6.25 billion. It was among the top gainers in the morning session today.
KUALA LUMPUR (Dec 7): MY E.G. Services Bhd (MYEG) announced today that it has entered into a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei) to obtain Malaysian Halal certification for the Chinese biopharma company’s COVID-19 vaccine and to exclusively distribute the vaccine in Malaysia for a 3-year period.
In a statement today, MYEG said the two companies have signed a Memorandum of Understanding, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and in achieving compliance to Halal status requirements to secure Halal certification from the Department of Islamic Development Malaysia (JAKIM).
MYEG said the commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., which is listed on the Shenzhen Stock Exchange and has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use. Zhifei is presently one of five Chinese companies conducting Phase 3 clinical trials of their COVID-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
Since Nov 1, 2020, MYEG has been appointed by the Malaysian Ministry of Health to develop and operate the MySafeTravel digital health pass system to facilitate inbound travellers’ compliance to mandatory COVID-19 testing and quarantine requirements.
In addition, MYEG also operates a one-stop portal for the COVID-19 screening of workers in the country, which includes a data sharing collaboration with the Department of Labour of Peninsular Malaysia.
MYEG was last traded at RM1.81, valuing it at RM6.61 billion.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Redplanet
352 posts
Posted by Redplanet > 2020-12-04 12:54 | Report Abuse
Lolx myeg JPJ project not NIIS... keep dreaming